San Francisco —June 28, 2023— In an industry-first, Phizzle, Inc. is now the only company to digitize the five scientific instruments that are the everyday “workhorses” of drug development and production.
“We have the only software-defined architecture in a production use case in the pharmaceutical industry,” said Ben Davis, Phizzle’s founder, and CEO. “Our first-of-its-kind architecture is making it possible to bring digitization to scientific instruments and unlock data that is largely manually captured today.”
The five instruments are all used in GMP/GLP [Good Manufacturing/Lab Practices] applications and include air particle counters, pH meters, balances, hot plate stirrer workstations, and zetasizers. The five instruments represent approximately 50 percent of the unit volume of lab equipment used in drug discovery and manufacturing, according to Davis.
Lena Wu, a Phizzle advisor, and veteran of the life sciences industry, said, “There are two really important goals that everybody in the drug manufacturing industry is focused on right now — one is efficiency, the other is data integrity.”
At scale, pharmaceutical manufacturers utilize thousands of these instruments each day. “These instruments are essentially the everyday workhorses of the drug development and drug manufacturing process, but because they are largely manually operated and require manual data capture, they become the Achille’s heel in the GMP environment where contemporaneous data capture is required,” Wu emphasized.
Phizzle’s EDGMaker platform makes it possible for pharmaceutical manufacturers to essentially eliminate the use of paper for these instruments and ensure data integrity.
“It’s never been possible to enable automated operations and contemporaneous data capture from these instruments — that’s the digital breakthrough,” said Davis. “No other software platform is remotely managing multiple types of instruments, brands, and models from a single UI in small molecule and biopharmaceutical applications, which is the key to data integrity.”
Customers using Phizzle’s EDGMaker have documented that the ability to remotely operate and digitize the data from these instruments has created significant operational cost savings from automated operations and the elimination of paper. Additionally, the leading cause of FDA warning letters to drug manufacturers in the last several years has been data integrity issues that are often due to human error, creating an industry-wide need for software solutions that can provide automated operations and data capture.
Watch Phizzle's “Big 5” webinar here
Phizzle’s EDGMaker is the world’s first and only scientific instrument platform to centrally manage drug production data.
Learn more at www.phizzle.com
